Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/31/11
End: 02/28/15
Due: 02/28/16
Phase: N/A
Priority: Normal
Start: 09/01/24
End: 04/30/28
Due: 04/30/29
Phase: N/A
Priority: Normal
Start: 09/01/15
End: 07/01/18
Due: 07/01/19
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer | NCT01428414 | Zhimin Shao | user2@example.com | None | 2011-08-31 | 2015-02-28 | 2016-02-28 | - | - | 2025-07-14 |
| PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer | NCT06612814 | Zhimin Shao | user2@example.com | None | 2024-09-01 | 2028-04-30 | 2029-04-30 | - | - | 2025-07-14 |
| Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer | NCT03507088 | Zhimin Shao | user2@example.com | None | 2015-09-01 | 2018-07-01 | 2019-07-01 | - | - | 2025-07-14 |